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Summary In order to determine whether mammary gland differentiation, which is known to protect this
organ from chemically induced carcinogenesis, can be stimulated in virgin rats by administration of a
progestagenic agent, medroxyprogesterone acetate (MPA) was given to 300 Sprague-Dawley virgin rats,
which at the ages of 45, 55, 65 and 75 days, groups I, II, III and IV respectively, had implanted an MPA
pellet of 0.5mg (low dose-LD) or 5.0mg (high dose-HD). Pellets were removed after 21 days, and 21 days
later five animals per group were killed for evaluation of mammary gland development. The remaining
animals received 8mg 7,12-dimethylbenz(a)-anthracene (DMBA) per lOOg body weight, and were killed after
24 weeks for evaluation of tumour incidence. Both age and treatment affected mammary gland structure and
had a significant interaction in the proportion of terminal end buds (TEBs) present. The number of TEBs
decreased as a function of age; treatment at both LD and HD did not modify the proportion of TEBs in
groups I and III; LD decreased their percentage in group II, and both doses markedly increased TEB
percentage in group IV animals. MPA LD treatment did not affect overall tumour and adenocarcinoma
incidence although group IV animals developed greater incidences than their respective controls. MPA HD
treated rats were 2.45 times more likely to develop tumours than their respective controls. Adenocarcinoma
incidence had a significant positive correlation with the percentage of TEBs present. It was concluded that
this progestagenic agent did not increase the risk of carcinoma development when administered to virgin rats
at the clinical dose used for contraception. However, a 10-fold dose increase resulted in a higher tumorigenic
response.
The development of mammary tumours induced in rats by
chemical carcinogens is inhibited if carcinogens are inocu-
lated after pregnancy and lactation (Dao et al., 1960; Russo
et al., 1979, 1982; Russo & Russo, 1987). The protective
effect induced by pregnancy and lactation is permanent,
since administration of 7,12-dimethylbenz(a)anthracene
(DMBA) to parous rats when the glands have regressed from
lactational hyperplasia to a resting stage fails almost comple-
tely to induce mammary carcinomas (Russo & Russo,
1978a,b, 1987). These observations indicate that it is not the
transient hormonal status occurring during pregnancy and
lactation that protects the mammary gland, but the perma-
nent changes induced by the reproductive phenomenon in
both gland structure and in the biological properties of the
glandular epithelium (Ciocca et al., 1982; Russo et al., 1977).
Therefore, in devising strategies for breast cancer prevention,
a logical approach is to stimulate mammary gland differen-
tiation before exposure to a carcinogen by physiological
mechanisms mimicking gestation. It is known that mammary
gland development and differentiation are under the control
of pituitary hormones. Decreased tumour incidence has been
observed when mammary growth has been prestimulated by
hypothalamic lesions or pituitary grafting (Clemens et al.,
1968; Welsch et al., 1968). Ovarian hormones, namely oes-
trogens, stimulate growth of the mammary epithelium
(Daniel et al., 1987; Haslam, 1988b; Welsch et al., 1979), and
progesterone determines the formation of alveoli (Freeman
& Topper, 1978). Since combinations of oestrogens and
progestagens are commonly used for contraception (Fechner,
1977; Russo et al., 1985a,b, 1986a; Welsch & Meites, 1969),
we considered that the clinical doses already tested in the
human female population provided an almost physiological
mechanism of hormonal simulation. However, even though
contraceptive agents have been widely studied, their effect on
mammary gland development and cancer remains contro-
versial and further understanding of their effect on mamm-
ary gland is necessary.
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We consider the induction of rat mammary carcinomas
with the chemical carcinogen DMBA to be an adequate
experimental model that mimics the human situation; its
study has allowed us to understand better the pathogenesis
of the disease and the factors that regulate the susceptibility
of the mammary gland to carcinogenesis, and to prevent the
development of mammary carcinoma by means of only one
pregnancy before carcinogen administration (Russo &
Russo, 1980a,b, 1986, 1987; Russo et al., 1982). This
protection is mediated by elimination, through differentia-
tion, of foci of high cellular proliferation, which are more
prone to bind carcinogenic agents (Russo & Russo, 1987).
The importance of this process is emphasised by the defini-
tive correlation found between the carcinogenic potency of
polycyclic aromatic hydrocarbons such as DMBA and their
interaction with tissue nucleophiles after metabolic activation
and binding to DNA (Brookes & Lawley, 1964; Duncan et
al., 1969; Huberman et al., 1972; Huberman & Sachs, 1974,
1977). The extent of polycyclic aromatic hydrocarbon bind-
ing to DNA is regulated by the rate of DNA synthesis
(Brookes & Lawley, 1964), which depends upon the age and
reproductive history of the subject (Russo et al., 1982; Janns
& Ben, 1978; Tay & Russo, 1981). Based upon this know-
ledge, and upon the observation that the mostly oestrogenic
hormone combination norethynodrel-mestranol exerts a truly
protective effect from chemically induced carcinogenesis
(Russo & Russo, 1986, 1987; Russo et al., 1985a,b 1986a;
Welsch & Meites, 1969), we considered it important to
determine what influence the treatment of virgin rats with
the purely progestagenic agent medroxyprogesterone acetate
(MPA) would have. This work was designed to test the effect
of MPA on the structure and rate of cell proliferation of the
virginal gland, whether it protected the organ from DMBA
induced carcinogenesis and whether there is a critical dose
and age for administering this hormonal agent in order to
induce a protective degree of gland differentiation. These
questions were addressed to determine whether this injectable
progestagen, which is used by millions of women worldwide
(Garza-Flores et al., 1985; Gray & Robertson, 1975;
Schwallie, 1974; Schwallie & Mohberg, 1977; Sun, 1982),
could also be used in breast cancer prevention.
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Materials and methods
Animals
All the experiments were carried out using virgin Sprague-
Dawley rats that were originally purchased from Charles
River Laboratory, Wilmington, MA. The animals were
maintained at a temperature of 24+ 1°C with controlled
lighting (12h light: 12h darkness). They received water and
food ad libitum.
Hormonal treatment
Three hundred virgin female Sprague-Dawley rats were
divided by age into four groups of 75 animals each and
identified as: group I, 45, group II, 55, group III, 65 and
group IV, 75 days old. Each group was further divided into
one control and two experimental groups, composed of 25
animals each. At the ages listed above one group of experi-
mental animals had implanted subcutaneously (s.c.) a pellet
that contained 0.5mg medroxyprogesterone acetate (MPA)
(Innovative Research of America, Rockville, MD), which
was identified as low dose (MPA LD). These pellets repre-
sented a dose of 3.12mgkg-1 per animal (group I);
2.80mgkg-1 (group II); 2.70mgkg-1 (group III) and
2.50mgkg-1 (group IV), which was estimated to be equiva-
lent to the amount of hormone administered to women
ranging in weight from 50 to 60kg, receiving an injection of
140mg Depo-Provera (Upjohn, Kalamazoo, MI) every 90
days (Garza-Flores et al., 1985). The second group of
experimental animals had implanted a 5.0mg MPA pellet, or
pharmacological dose, which was a 10-fold increase above
the physiological dose; it was identified as high dose (MPA
HD). The pellets had a 21-day hormone release period.
Control animals received cholesterol pellets. All pellets were
implanted s.c. in the interscapular area using a 10 gauge steel
trocar (Innovative Research of America, Rockville, MD) to
animals under light ether anaesthesia.
The number of animals per group, the length of treatment
and the selection of two doses of hormones was designed
following the guidelines set at the Second International
Symposium of the Society of Toxicologic Pathologists on
Design of Carcinogenesis Studies (1983).
Experimental protocol
Both control and experimental animals in the four groups
had the pellets left in place for 21 days, then the remainders
of the pellets were removed and weighed. Hormone release
was calculated from weight lost by the pellets, and was
estimated to be 0.014+0.010mgkg- day-1. The animals
were left undisturbed for an additional 21 days to allow for
the mammary gland parenchyma to return to a resting stage
(Ciocca et al., 1982). At this time five animals per group
were randomly selected for study of cell kinetics and mamm-
ary gland structure; they constituted the 0 time controls. The
remaining animals received carcinogen for the study of
tumour development. Study of 0 time controls and adminis-
tration of DMBA for carcinogenic response determination
were carried out 21 days after pellet removal, and therefore
the actual age of the animals in each group was 87, 97, 107
and 117 days respectively at the times both of collection of
mammary glands for the study of gland structure and cell
kinetics, and of carcinogen administration.
Effect of treatment on mammary gland structure Forty-two
days after pellet implantation, five animals from each of the
groups were killed and the mammary glands were removed
attached to the skin pelt, stretched on a corkboard, fixed in
10% neutral buffered formalin and processed for whole
mount preparation as described by Russo et al. (1988a).
Mammary gland development was evaluated by a count
under a stereomicroscope of the number of terminal struc-
tures, namely terminal end buds (TEBs), terminal ducts
(TDs) and alveolar buds (ABs); alveolar buds were counted
together with lobules. The terminal structures were counted
along the entire peripheral area of the mammary paren-
chyma of each gland, by applying criteria previously des-
cribed (Russo, 1983; Russo & Russo, 1978b, 1980b) and
expressed as a percentage of the total number of structures
counted. We have previously described the morphology of
the mammary gland as composed of ductal structures with
variable lateral branching ending in TEBs, TDs, ABs or
lobules (Russo & Russo, 1978a,b, 1987; Russo et al., 1979,
1982), and have also reported that mammary glands located
in the thoracic region develop at a different rate from those
located in the abdominal region (Russo et al., 1986b; Russo
& Russo, 1987). Since this asynchronous development
appeared to be responsible for the higher tumorigenic res-
ponse of these glands after carcinogen administration, we
focused our study on mammary glands located in the
thoracic region. Quantitative evaluation of abdomino-
inguinal mammary gland development has been published
elsewhere (Russo et al., 1985a,b, 1986a,b; Russo & Russo,
1987).
Carcinogen administration Twenty-one days after pellet
removal the remaining 20 animals from each group were
weighed, then received a single intragastric dose of 8mg
DMBA (Eastman Organic Chemicals, Rochester, NY) per
100 gram body weight, dissolved in corn oil. Controls
consisted of age-matched animals receiving the vehicle only.
Animals were palpated twice a week for detection of tumour
development. Tumour size was measured in two dimensions
with a vernier caliper. Date of tumour appearance, tumour
location and growth rate were recorded. All the animals
were killed 24 weeks post-DMBA administration. The
mammary glands were dissected from the skin and processed
for whole mount (Russo et al., 1988a). Microscopic lesions
identified under the stereomicroscope were photographed,
dissected and embedded in paraffin for histological correla-
tion. Grossly palpable tumours were fixed in 10% buffered
formalin and processed for light microscopic examination.
All palpable and microscopic tumours identified in whole
mount preparations were sectioned at 5pm thickness and
stained with Haematoxylin and Eosin. Tumours were classi-
fied by applying the criteria developed in the consensus on
classification of rat mammary tumours (Russo et al., 1988b).
Animals that died within 24-48 h of DMBA adminis-
tration due to adrenal necrosis or those that died without a
complete autopsy, and the mammary glands and tumours of
which were not examined histologically, were deleted from
the study.
Statistical analysis
The effects of age and MPA treatment at both doses on the
change in body weight and on the percentage of mammary
gland terminal structures (TEBs, TDs and ABs) were
analysed using a two factor analysis of variance (Kleinbaum
& Kupper, 1978). A multiple range test was used for post-
hoc comparison of means of effects. Bonferroni's technique
was used to adjust for post-hoc comparison of group means
(Zar, 1984).
The proportions of DMBA-induced tumours and DMBA-
induced adenocarcinomas were analysed using a logistic
regression (Fleiss, 1981). The logistic regression model for
dichotomous dependent variables predicts the probability
that a rat with given characteristics (i.e. MPA dose, percen-
tage of TEBs and age) will develop tumours. Tumour
development is described in terms of the odds-ratio, which is
the ratio of the proportion of rats with tumours in the
hormonally treated experimental group and the proportion
of rats with tumours in the control group, and is computed
for characteristics significant in the logistic model. A 95%
confidence interval is given for these estimates (Fleiss, 1981).
Pearson's correlation coefficient (Zar, 1984) was used to
measure the association between the percentage of TEBs and
the number of adenocarcinomas observed for each group.212 I.H. RUSSO et al.
Results
Body weight
The animals in the four groups differed in initial body
weight, exhibiting a natural increase with age (Table I). The
increase in weight observed by 42 days after pellet implan-
tation was not linear. Control animals of group I gained
proportionally more weight than those of groups II, III and
IV, whose weight gains were similar (Table I). When treat-
ment was initiated at the age of 45 days (group I), treated
animals gained less weight than the age-matched controls
(Table I). The difference was statistically significative
between group I control and group I MPA LD (t=2.665,
P=0.019), and group I MPA HD, (t=5.20, P<0.001).
Animals of both treated and control groups II, III and IV
gained approximately the same body weight (Table I).
Mammary gland structure
The mammary glands of group I control animals showed a
varied architecture, being composed of areas containing thin
long ducts ending in prominent TEBs (Russo & Russo,
1987), which constituted approximately 30% of the terminal
structures (Table LI), and areas exhibiting diffuse lateral
branching, ending in small or moderately developed ABs.
With ageing the percentage of TEBs progressively decreased
to 15, 10, and 5% in the mammary gland of groups II, III
and IV control animals, respectively (Table II). There were
significant differences in the percentage of TEBs between
these four age groups (two-sample t tests, P<0.0001).
The proportion of TEBs in the mammary glands was
significantly affected by both age and MPA treatment. There
Table I Effect of MPA treatment on body weight
Groupa
I II III IV
Control-beforeb 159+109 177+11 183 + 4 198+44
Control-afterC 272+25 255+15 253+16 278+15
Differenced 113+18 78+13 70+15 80+16
MPA LD-beforee 161+ 7 176+ 5 184+ 6 195+ 7
MPA LD-after 260+33 265+23 259+14 280+20
Difference 99+16 89+24 75+ 17 85+ 18
MPA HD-beforef 156+ 9 180+ 7 192+ 8 201+ 8
MPA HD-after 241+24 259+19 264+11 291+18
Difference 85+26 79+19 72+13 90+19
aGroups divided by age in days. I, 45; II, 55; III, 65; IV, 75.
bBody weight determined at the beginning of treatment.
CBody weight determined 42 days after pellet implant.
dDifferences in body weight (c-b). CMPA LD: medroxyprogesterone acetate low dose.
fMPA HD: medroxyprogesterone acetate high dose.
gBody weight in grams, mean+standard deviation.
was a statistically significant interaction between age and
treatment group (F=10.87, d.f.=6,47, P<0.0001). The pro-
portion of TEBs in the mammary gland of animals of
groups I and III, whose treatments with both MPA LD and
MPA HD started when they were 45 and 65 days old
respectively, was not significantly different from their
respective control groups. Group II MPA LD treated ani-
mals were found to have a significantly lower percentage of
TEBs than their respective control group (t =2.91,
P=0.012), but no significant differences in TEB percentage
were observed in the HD treated animals. For group IV the
percentage of TEBs in both the low dose MPA (t=5.02,
P<0.001) and high dose MPA (t=7.23, P<0.001), was
significantly higher than for their respective controls
(Table II). The reduction in percentage of TEBs as a func-
tion of age was associated with an increase in other terminal
ductal structures such as ABs, TDs or lobules (Table II).
The only significant factor in the analysis of variance of
the percentage of TDs was initial age (F=8.59, d.f.=3,64,
P=0.0001). Group III animals had a significantly higher
percentage of TDs than animals in the other age groups
(Table II).
There was a significant interaction between treatment and
age in the analysis of variance in the percentage of ABs
(F=2.72, d.f. =6,64, P=0.0223). The relationship between
the percentage of ABs and dose changed with age; the
percentage of ABs increased with dose in group I animals;
changes in AB percentage were not significant in groups II
and III animals, but this percentage decreased with dose in
animals of group IV (Table II).
Tumorigenic response
Administration of a single intragastric dose of DMBA
induced palpable tumours in both control and treated
animals (Table III) (Figure 1). Analysis of data revealed a
natural decline in susceptibility to carcinogenesis with
increasing age at the time of carcinogen administration. The
incidence of tumours in general declined and the tumour
latency period lengthened in control animals treated with
cholesterol pellets after the age of 45 days and subsequent
carcinogen treatment (Table III). Age (L.R. = 10.90, d.f. =3,
P=0.0123) and treatment (L.R.=6.59, d.f.=2, P=0.037)
were both significant factors in predicting the probability of
developing a tumour using a logistic regression model, but
there was no interaction present.
There was no difference in the probability of developing a
tumour between control and low dose treated groups. Rats
treated with a high dose of MPA, on the other hand, were
2.45 times more likely to develop a tumour than their age
matched controls, with 95% confidence intervals of 1.103
and 5.451. Younger rats appeared to be more susceptible to
tumorigenesis (Table III, Figure 1). The odds of a group II
animal developing a tumour were 0.197 compared to group I
Table II Effect of MPA treatment on percentage of terminal ductal structures in the rat
mammary gland
Group
Structure Treatment I II III IV
TEBa Control 30.08 + 6.58d 15.08 + 2.94 10.32+2.11 4.67+ 1.59
MPA LD 35.20+ 5.58 8.38+ 3.60 9.89+2.16 15.74+ 2.23
MPA HD 28.35+ 7.55 19.33+ 4.15 8.50+3.30 19.32+ 1.47
TDb Control 40.73 + 8.51 62.61 + 7.94 61.80+4.80 47.49+20.92
MPA LD 25.88+ 12.39 43.98+ 9.56 54.20+7.96 52.75+ 6.14
MPA HD 35.71 + 3.27 36.28+11.54 67.68+4.78 48.67+ 5.10
AB-Lobc Control 30.36+ 10.28 32.47+ 10.01 28.80+6.39 47.88+21.77
MPA LD 38.42+11.97 43.64+ 8.24 35.60+7.46 32.00+ 5.84
MPA HD 45.02+ 7.36 39.80+13.10 24.00+6.68 29.00+ 4.99
aTEB: terminal end bud.
bTD: terminal duct.
CAB-Lob: alveolar buds - lobules.
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Table III Influence of MPA treatment on the incidence of DMBA-induced mammary tumours
Number of animals
MPA DMBA Evaluated for
Groups? Treatment treated treated tumorigenesis
I
I
I
II
II
II
III
III
III
IV
IV
IV
Control
MPA LD
MPA HD
Control
MPA LD
MPA HD
Control
MPA LD
MPA HD
Control
MPA LD
MPA HD
25
25
25
25
25
25
25
25
25
25
25
25
20
20
20
20
20
20
20
20
20
20
20
20
aGroups as in Table I.
bLatency period in days: mean+standard deviation.
12
11
8
15
18
17
12
15
16
18
16
16
Animals
with
tumours
No. %
9 75.0
9 81.8
7 87.5
7
5
12
6
7
10
8
10
11
100-
40
40
11 111 I
Groups
Figure 1 Tumour incidence: percentage of animals with mam-
mary gland tumours (ordinate) developed 24 weeks post-DMBA
administration by: control (hatched), MPA LD (medroxy-
progesterone acetate low dose; filled) and MPA HD (medroxy-
progesterone acetate high dose; open) treated rats (abscissa).
Groups: treament started at 45 days (I), 55 days (II), 65 days
(III), 75 days (IV).
animals, with 95% confidence intervals of 0.068 and 0.574.
Similarly, the odds were 0.241 and 0.305 for animals in
group III and IV respectively, versus group I, with confi-
dence intervals of 0.080, 0.720 and 0.105, 0.889.
When only adenocarcinomas were considered (Table III,
Figure 2) it was observed that their incidence was lowest in
group II MPA LD treated animals, and second lowest in
: 60
40-
0)
i
C
20)
~0
C 1
11 111 ~~~~IV
Groups
Figure 2 Adenocarcinoma incidence: percentage of animals with
mammary gland adenocarcinomas (ordinate) developed 24 weeks
post-DMBA administration. Groups and treatments (abscissa) as
in Figure 1.
46.7
27.8
70.6
50.0
46.7
62.5
44.4
62.5
68.8
Animals with
adenocarcinomas
No. %
5 41.7
5 45.5
4 50.0
6
1
6
5
4
6
4
7
7
40.0
5.6
35.3
41.7
26.7
37.5
22.2
43.8
43.8
No. tumours
per animal
1.75
1.55
1.75
1.27
0.50
2.88
1.58
0.60
1.00
1.22
1.94
2.31
Tumour
latency period
81.5+ 4.01b
114.8+34.6
115.5+34.3
120.5+30.0
73.0+ 15.0
41.0+ 5.0
110.0+30.0
60.0+ 32.0
90.0+30.0
177.0+25.0
95.0+ 11.0
120.0+30.0
group III MPA LD (Table III, Figure 2). Even though in
group IV control adenocarcinoma incidence was lower than
in any other control group, a two-fold increase over the
respective controls occurred in groups IV MPA LD and HD
treated animals; no change with respect to the controls was
observed in MPA LD or HD treated group I animals or in
HD treated groups II and III animals (Table III, Figure 2).
When correlated by dose-age groups, the incidence of adeno-
carcinomas was significant and positively correlated with the
average percentage of TEBs (r=0.644, d.f.=10, P=0.026).
Average percentage of TDs and ABs for the 12 dose-ages
did not significantly correlate with the incidence of
adenocarcinomas.
Discussion
The susceptibility of the mammary gland to chemically
induced carcinogenesis is considerably diminished or abo-
lished by hormonally induced differentiation of this organ;
this phenomenon is mediated by either pregnancy (Russo &
Russo, 1986, 1987; Russo et al., 1982) or exogenously
administered hormones, either contraceptive agents such as
norethynodrel-mestranol or the placental hormone chorionic
gonadotropin (Russo & Russo, 1987). These observations led
us to test whether treatment of virgin rats with the progesta-
genic agent MPA before the administration of DMBA
protected the mammary gland from neoplastic transforma-
tion, and whether this compound was more efficient than the
estrogenic contraceptive norethynodrel-mestranol (Russo et
al., 1988a). We observed that treatment with the dose
clinically used for contraception in Depo-Provera (Garza-
Flores et al., 1985) affected the mammary gland structure
and its tumorigenic response differently from treatment with
a 10-fold higher or pharmacological dose. MPA low dose
treatment resulted in statistically significant reductions in
percentage of TEBs only in animals whose treatment started
at age 55 (Group II), which correlated with the observed
lower tumour and adenocarcinoma incidence. However,
although age and treatment were significant factors in pre-
dicting tumour development, there was no interaction
present and low dose treatment did not modify the
probability of a rat developing a tumour. Rats treated with
the high dose, on the other hand, were 2.45 times more
likely to develop a tumour than controls. The effect of both
MPA LD and MPA HD on mammary gland structure was
manifested in the 75-day-old animals as an inhibition of
mammary gland differentiation, namely inhibition of the
progression of TEBs to ABs and of these to lobules, which
resulted in a relative increase in the number of TEBs over
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the number normally found in age-matched animals. These
structural changes had a statistically significant correlation
with the incidence of adenocarcinomas developed after expo-
sure to carcinogen. These results contrasted markedly with
those observed in rats treated with both low and high dose
norethynodrel-mestranol (Russo et al., 1988a), in which the
hormonal treatment resulted in a dose-dependent significant
reduction in percentage of TEBs and a concomitant reduc-
tion in DMBA-induced tumour and adenocarcinoma inci-
dence. A protective effect of ovarian hormones has been
reported by various authors (Kledzik et al., 1974; Stern &
Mickey, 1969; Welsch & Meites, 1969). Huggins et al. (1962)
observed that 17B-oestradiol had a protective effect when
given in combination with progesterone, decreasing cancer
incidence when the hormones were administered 15 days
post-DMBA instillation, whereas pregnancy and progester-
one alone accelerated tumour growth. Increased tumour
incidence as a consequence of progestagenic hormonal treat-
ment has been reported in other species such as beagle dogs,
which develop malignant and metastatic mammary tumours
after treatment with low and high doses of depot MPA, and
rhesus monkeys develop endometrial carcinomas after treat-
ment with high dose of this hormone (Concannon et al.,
1980; Fowler et al., 1977; Frank et al., 1979). In Balb/c mice,
depot MPA treatment induces a high incidence of invasive
mammary adenocarcinomas (Lanari et al., 1986a,b). All of
these studies, however, attest to the carcinogenic effect of the
hormone per se; ours is the first study that reports the
influence of MPA on mammary gland structure before
exposure to DMBA, thus acting as a modifier of the
response of this organ to a chemical carcinogen. It remains
to be elucidated whether the effect of this acetoxy-
progesterone derivative, which is qualitatively similar to but
more potent than progesterone (Edgren, 1969) on mammary
gland development, is mediated by its progestagenic, andro-
genic or synandrogenic effects (MacLaughlin & Richardson,
1979).
The focus in recent years has been primarily on the role of
oestrogens in the development and promotion of growth of
neoplasias in secondary sex structures, including the breast
(Van Boagert, 1978a,b). Progesterone, in contrast, is con-
sidered to be a neutraliser of oestrogen and oestrogenic
action. However, there is evidence that progesterone stimu-
lates the incorporation of labelled thymidine into human
mammary ductal epithelial cells (Van Boagert, 1978a,b),
mainly the epithelial cells of the interlobular ducts. Those
findings are consistent with the elevation in DNA-LI
observed in MPA treated animals (Russo & Russo, 1988);
however, this is not a universal phenomenon, but varies in
the different compartments of the gland and with the age of
the animal, which suggests that local regulatory factors or
hormone receptor levels might be modulating the response of
the glandular epithelium to this hormone. Our observations
that animals treated at the age of 45 days responded
differently to MPA treatment from animals treated at older
ages are supported by the observations that the effect of
progesterone on mammary gland epithelial proliferation
differs depending upon the age of the animal (Haslam,
1988a), since the TEB of ovariectomised 5-week-old mice
responds with cell proliferation to oestrogen (Daniel et al.,
1987; Haslam, 1988b) whereas progesterone strongly stimu-
lates DNA synthesis in 10-week-old animals (Haslam,
1988a). It is possible to postulate that the same mechanisms
are operating in the rat, since the response to treatment
varied with age. In the DMBA rat mammary carcinoma
model, progesterone, like oestradiol, reduces the latency
period and increases the size and number of tumours
developed when it is administered during the latent period
following DMBA (Huggins et al., 1958; Jabara, 1967; Kelly
et al., 1977), although progesterone does not maintain
hormone dependent carcinomas in castrated rats
(Van Boagert, 1978b).
The possible role of progestagenic contraceptives in the
aetiology of breast cancer is far from being clarified.
Nevertheless, epidemiological studies have linked the use of
high progestagen contraceptive agents administered before a
full term pregnancy to a higher risk of developing breast
(Pike et al., 1981, 1983) and cervical cancer (WHO Collabor-
ative Study of Neoplasia and Steroid Contraceptive, 1984).
Epidemiological observations in general tend to consider that
combination oral contraceptives have no influence on breast
cancer risk (Rosner & Lane, 1986; Thomas, 1978; Vessey et
al., 1979; Wang & Fentiman, 1985), a finding confirmed by
experimental data showing that the combination compound
norethyndrel-mestranol, which in the rat is mostly oestro-
genic, has a protective effect from chemically induced carci-
nogenesis (Russo et al., 1985a,b, 1986a; Russo & Russo,
1986, 1987; Stern & Mickey, 1969; Welsch & Meites, 1969),
whereas the progestagenic compound MPA tends to increase
tumour incidence. Our studies allowed us to conclude that in
the DMBA-rat mammary gland system, MPA treatment at
the dose used for contraception does not significantly affect
mammary gland development, and therefore does not modify
the response of the organ to the administration of a chemical
carcinogen, whereas a 10-fold increase in dose results in
inhibition of gland differentiation in the group treated at 75
days of age, with an increase in number of targets and a
consequent increase in tumour incidence. These results
emphasise the need for further investigation on the role of
natural and synthetic progestagenic agents on mammary
gland development and differentiation, especially with
regards to the influence of age and/or receptor content in the
response of the gland to these hormones, and how they will
interact in the modulation of the gland's susceptibility to
carcinogenesis.
This investigation was supported by PHS grant no. CA35699,
National Cancer Institute, DHSS.
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